Alemtuzumab and rituximab
PreclinicalMonoclonal antibody
Alemtuzumab and rituximab is one of 51 small molecule programs targeting Aplastic Anemia. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Aplastic Anemia
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Promacta
GSKPhase 3
Atgam
NovartisPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Doptelet
AAkarx
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cysteine Hydrochloride
NovartisPhase 3
Alkeran
AApotex Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alemtuzumab and rituximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details